The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Revvity is positioning its technologies as a connected engine for discovery
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The new capital is expected to fund the company through 2029
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
